Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program

BACKGROUND: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Here, we performed an integrated analysis of malignancy events from the tofacitinib phase 3 UC clinical development program (excluding nonmelanoma skin cancer [NMSC]). METHODS: Dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lichtenstein, Gary R, Rogler, Gerhard, Ciorba, Matthew A, Su, Chinyu, Chan, Gary, Pedersen, Ronald D, Lawendy, Nervin, Quirk, Daniel, Nduaka, Chudy I, Thorpe, Andrew J, Panés, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128409/
https://www.ncbi.nlm.nih.gov/pubmed/32766762
http://dx.doi.org/10.1093/ibd/izaa199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128409/
https://www.ncbi.nlm.nih.gov/pubmed/32766762
http://dx.doi.org/10.1093/ibd/izaa199

Ejemplares similares